Dementia risk varies by type of androgen deprivation therapy
- PDF / 151,331 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 3 Downloads / 206 Views
1
Dementia risk varies by type of androgen deprivation therapy The risk of dementia varies by the type of androgen deprivation therapy (ADT) among patients with prostate cancer, with an increase in such risk with the use of anti-androgen monotherapy. These are the main findings of a nationwide cohort study from Taiwan that examined the association between different types of ADT and the risk of subsequent dementia, including Alzheimer’s disease (AD), among patients with prostate cancer newly diagnosed between January 2008 through December 2015. Patients were followed through December 2017. The analysis of data from 23 651 patients with newly diagnosed prostate cancer showed that 11 817 (50%) received gonadotropin-releasing hormone (GnRH) agonists (leuprolide, goserelin, triptorelin or buserelin), 4054 (17.1%) received anti-androgen monotherapy (including cyproterone acetate, bicalutamide or flutamide), 876 (3.7%) underwent orchiectomy, and 6904 (29.2%) did not receive ADT. Over a median follow-up period of 3.46 years, the crude incidence rates of all-cause dementia and AD for the entire cohort were 1.76 and 0.41 per 100-person-years, respectively. Compared with patients who did not receive ADT, anti-androgen monotherapy was associated with an increased risk of all-cause dementia (hazard ratio [HR] 1.34; 95% CI 1.16–1.55) and AD (HR 1.52; 95% CI 1.13–2.04). The use of GnRH agonists or orchiectomy was not associated with an increased risk of dementia or AD. Huang W-K, et al. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan. JAMA Network Open : 31 Aug 2020. Available from: URL: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2770047?utm_source=silverchair&utm_medium=email&utm_campaign=article_alert803501180 jamanetworkopen&utm_content=wklyforyou&utm_term=090220
0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Sep 2020 No. 1821
Data Loading...
